Krystal Biotech (KRYS) Stock Forecast & Price Target

Compare

581 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KRYS Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Krystal

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KRYS Stock 12 Month Forecast

Average Price Target

$221.00

▲(11.66% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $221.00 with a high forecast of $255.00 and a low forecast of $198.00. The average price target represents a 11.66% change from the last price of $197.93.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","157":"$157","190":"$190","223":"$223","256":"$256"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$255.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":221,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$221.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":198,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$198.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,157,190,223,256],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,197.51,201.9323076923077,206.35461538461539,210.77692307692308,215.19923076923075,219.62153846153845,224.04384615384615,228.46615384615384,232.88846153846154,237.3107692307692,241.7330769230769,246.1553846153846,250.5776923076923,{"y":255,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,197.51,199.31692307692308,201.12384615384616,202.93076923076922,204.7376923076923,206.54461538461538,208.35153846153847,210.15846153846152,211.9653846153846,213.7723076923077,215.57923076923078,217.38615384615383,219.19307692307692,{"y":221,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,197.51,197.5476923076923,197.5853846153846,197.62307692307692,197.66076923076923,197.69846153846154,197.73615384615385,197.77384615384614,197.81153846153845,197.84923076923076,197.88692307692307,197.92461538461538,197.9623076923077,{"y":198,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":176.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.91,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.36,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$255.00

Average Price Target$221.00

Lowest Price Target$198.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gavin Clark-Gartner

Evercore ISI

$200→$218

Buy

10.14%

Upside

Reiterated

11/04/25

Evercore ISI Sticks to Their Buy Rating for Krystal Biotech (KRYS)

Ritu Baral

TD Cowen

$202

Buy

2.06%

Upside

Reiterated

11/03/25

Krystal Biotech's Strong Financial Performance and Strategic Initiatives Justify Buy Rating

Sami Corwin

William Blair

―

Buy

―

Reiterated

11/03/25

Positive Outlook for Krystal Biotech: Growth Potential Driven by Vyjuvek, Clinical Pipeline, and Global Expansion

Geulah Livshits

Chardan Capital

$216→$220

Buy

11.15%

Upside

Reiterated

11/03/25

Analysts Are Bullish on Top Healthcare Stocks: Krystal Biotech (KRYS), Xenon (XENE)

William Maughan

Clear Street

$212→$217

Buy

9.63%

Upside

Reiterated

11/03/25

Krystal Biotech price target raised to $217 from $212 at Clear StreetKrystal Biotech price target raised to $217 from $212 at Clear Street

Yigal Nochomovitz

Citi

$166→$198

Hold

0.04%

Upside

Reiterated

11/03/25

Hold Rating Maintained Amid Mixed Market Performance and Future Pipeline PotentialWe’ve slightly adjusted our market penetrations to reflect incrementally higher market share... The net result is an increase in our TP to $198 from $166.

Joseph Pantginis

H.C. Wainwright

$240

Buy

21.25%

Upside

Reiterated

11/03/25

Krystal Biotech (KRYS) Gets a Buy from H.C. Wainwright

Alec Stranahan

Bank of America Securities

$182→$255

Buy

28.83%

Upside

Reiterated

10/17/25

Krystal Biotech price target raised to $255 from $182 at BofAKrystal Biotech price target raised to $255 from $182 at BofA

Debjit Chattopadhyay

Guggenheim

$189→$224

Buy

13.17%

Upside

Reiterated

10/16/25

Krystal Biotech price target raised to $224 from $189 at GuggenheimKrystal Biotech price target raised to $224 from $189 at Guggenheim

Joshua Schimmer

Cantor Fitzgerald

$215

Buy

8.62%

Upside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on Krystal Biotech (KRYS)

Andrea Newkirk

Goldman Sachs

$194

Buy

-1.99%

Downside

Reiterated

07/25/25

Positive Phase 1 Trial Results for KB304 Bolster Buy Rating for Krystal Biotech Amidst Promising Market Potential

Roger Song

Jefferies

$245

Buy

23.78%

Upside

Initiated

03/05/25

Krystal Biotech's Growth Potential: Strong Vyjuvek Launch and Promising PipelineWe see steady growth to achieve blockbuster status in few years, deepening penetration by accessing global and ocular market. Co has many dev program in CF/ AATD/ oncology/ dermatology based on proprietary, in house gene delivery technology to drive add'l upside. We initiate at Buy with PT of $245.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gavin Clark-Gartner

Evercore ISI

$200→$218

Buy

10.14%

Upside

Reiterated

11/04/25

Evercore ISI Sticks to Their Buy Rating for Krystal Biotech (KRYS)

Ritu Baral

TD Cowen

$202

Buy

2.06%

Upside

Reiterated

11/03/25

Krystal Biotech's Strong Financial Performance and Strategic Initiatives Justify Buy Rating

Sami Corwin

William Blair

―

Buy

―

Reiterated

11/03/25

Positive Outlook for Krystal Biotech: Growth Potential Driven by Vyjuvek, Clinical Pipeline, and Global Expansion

Geulah Livshits

Chardan Capital

$216→$220

Buy

11.15%

Upside

Reiterated

11/03/25

Analysts Are Bullish on Top Healthcare Stocks: Krystal Biotech (KRYS), Xenon (XENE)

William Maughan

Clear Street

$212→$217

Buy

9.63%

Upside

Reiterated

11/03/25

Krystal Biotech price target raised to $217 from $212 at Clear StreetKrystal Biotech price target raised to $217 from $212 at Clear Street

Yigal Nochomovitz

Citi

$166→$198

Hold

0.04%

Upside

Reiterated

11/03/25

Joseph Pantginis

H.C. Wainwright

$240

Buy

21.25%

Upside

Reiterated

11/03/25

Krystal Biotech (KRYS) Gets a Buy from H.C. Wainwright

Alec Stranahan

Bank of America Securities

$182→$255

Buy

28.83%

Upside

Reiterated

10/17/25

Krystal Biotech price target raised to $255 from $182 at BofAKrystal Biotech price target raised to $255 from $182 at BofA

Debjit Chattopadhyay

Guggenheim

$189→$224

Buy

13.17%

Upside

Reiterated

10/16/25

Krystal Biotech price target raised to $224 from $189 at GuggenheimKrystal Biotech price target raised to $224 from $189 at Guggenheim

Joshua Schimmer

Cantor Fitzgerald

$215

Buy

8.62%

Upside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on Krystal Biotech (KRYS)

Andrea Newkirk

Goldman Sachs

$194

Buy

-1.99%

Downside

Reiterated

07/25/25

Positive Phase 1 Trial Results for KB304 Bolster Buy Rating for Krystal Biotech Amidst Promising Market Potential

Roger Song

Jefferies

$245

Buy

23.78%

Upside

Initiated

03/05/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Krystal Biotech

1 Month

xxx

Success Rate

8/12 ratings generated profit

Average Return

+3.62%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.62% per trade.

3 Months

xxx

Success Rate

10/17 ratings generated profit

Average Return

+8.72%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +8.72% per trade.

1 Year

Geulah LivshitsChardan Capital

Success Rate

16/17 ratings generated profit

Average Return

+42.95%

reiterated a buy rating 7 days ago

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +42.95% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+87.35%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +87.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KRYS Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KRYS has received 16 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KRYS average Analyst price target in the past 3 months is 221.00.

Each month's total comprises the sum of three months' worth of ratings.

KRYS Financial Forecast

KRYS Earnings Forecast

Next quarter’s earnings estimate for KRYS is $1.50 with a range of $0.75 to $1.93. The previous quarter’s EPS was $2.66. KRYS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year KRYS has Preformed in-line its overall industry.

KRYS Sales Forecast

Next quarter’s sales forecast for KRYS is $105.54M with a range of $100.00M to $116.96M. The previous quarter’s sales results were $97.80M. KRYS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year KRYS has Preformed in-line its overall industry.

KRYS Stock Forecast FAQ

What is KRYS’s average 12-month price target, according to analysts?

Based on analyst ratings, Krystal Biotech’s 12-month average price target is 221.00.

What is KRYS’s upside potential, based on the analysts’ average price target?

Krystal Biotech has 11.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KRYS a Buy, Sell or Hold?

Krystal Biotech has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Krystal Biotech’s price target?

The average price target for Krystal Biotech is 221.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $255.00 ,the lowest forecast is $198.00. The average price target represents 11.66% Increase from the current price of $197.93.

What do analysts say about Krystal Biotech?

Krystal Biotech’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of KRYS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Krystal Biotech (KRYS) Stock Forecast & Price Target

KRYS Analyst Ratings

KRYS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Krystal Biotech

KRYS Analyst Recommendation Trends

KRYS Financial Forecast

KRYS Earnings Forecast

KRYS Sales Forecast

KRYS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts